Saudi Pharmaceutical Industries & Medical Appliances Corp. · TADAWUL:2070
Saudi Pharmaceutical Industries & Medical Appliances — H1 2025 Earnings Presentation
15 slides from Saudi Pharmaceutical Industries & Medical Appliances's earnings presentation, Aug 11, 2025
Slide 1: Earnings Presentation 1H 2025
Earnings Presentation 1H 2025 11 August, 2025
Slide 2: 1H 2025 Performance Highlights & Strategy
1H 2025 Performance Highlights & Strategy
Slide 3: Disciplined Cost Management Supports EBITDA Margin Expansion
Disciplined Cost Management Supports EBITDA Margin Expansion 1H 2025 performance overview Key 1H 2025 Developments R&D and Operations R&D Spending Production Volume Productivity As % of 1H25 revenue -18% vs. 1H24 Optimized facility utilization, 3.2% 850 mn units improved manufacturing efficiency Mar
Slide 4: Top Rankings in High-Value Therapeutic Areas
Top Rankings in High-Value Therapeutic Areas SPIMACO is KSA private market leader SPIMACO’s Private Market Share and Rank1 Therapeutic Area Share of Private Market1 (Company's Private Market Share in %, Rank) (Therapeutic Area Share of Private Market in %) Urology 18% #1 Urology 4% 100% Anti Infecti
Slide 5: Leveraging Market Trends to Support Future Performance
Leveraging Market Trends to Support Future Performance Saudi Arabia market opportunity Gross Market Size How Do We Play the Trends in KSA? Value Sales (¥ bn) +9% CAGR Focus on chronic and lifestyle 55.6 diseases 47.9 Concentrate 41.9 on regional 35.9 36.5 Biosimilars 34.4 market Increase differentia
Slide 6: 1H 2025 Financial Performance
1H 2025 Financial Performance
Slide 7: 1H 2025: Higher Profitability Despite Cost Pressure
1H 2025: Higher Profitability Despite Cost Pressure P&L trends and highlights in 1H 2025 P&L Highlights Net Profit Development (2Q25) (¥ mn) ¥ mn 2Q 2025 2Q 2024 Δ% 1H 2025 1H 2024 Δ% Revenue 401 373 +7% 886 849 +4% 18 27 12 1 36 Cost of revenue (207) (197) +5% (463) (422) +10% (9) (13) Gross profit
Slide 8: Private and Government Channels – The Key Contributors to Pharma Revenue
Private and Government Channels – The Key Contributors to Pharma1 Revenue Revenue: pharma revenue1 by channel Revenue by Channel2 Revenue by Channel Development2 (%) (%, ppts) Private 65.1% 59.3% +5.8 ppts +5.2 ppts 100.0% 100.0% International 7.2% -0.9 ppts 13.9% -3.4 ppts -6.8 ppts Government 22.2
Slide 9: Disciplined Cost Management Drives Lower Operating Expenses
Disciplined Cost Management Drives Lower Operating Expenses Key operating costs trends Key Operating Expenses (SG&A and R&D) Selling and Marketing Expenses Development (¥ mn, % of Revenue) (¥ mn) -6% +1% 152 11 (22) 3 142 (0) (1) 197 175 +93% -20% -11% -32% +15% 8.4% S&M Advertising & Salaries & Tra
Slide 10: Stronger Liquidity and Optimized Net Debt Support Financial Flexibility
Stronger Liquidity and Optimized Net Debt Support Financial Flexibility Balance sheet trends Balance Sheet Highlights Net Debt1 ¥ mn 2Q 2025 4Q 2024 Δ% 1Q 2025 Δ% (¥ mn) Total Non-Current Assets 1,967 1,963 +0% 1,970 -0% +4% Total Current Assets 2,539 2,356 +8% 2,519 +1% Total Assets 4,505 4,319 +4%
Slide 11: Operating Cash Flow Recovers on Improved Working Capital Discipline
Operating Cash Flow Recovers on Improved Working Capital Discipline Cash flow trends Cash Flow Highlights Cash Flow Dynamics2 (1H25) ¥ mn 1H 2025 1H 2024 Δ% (¥ mn) 110 58 266 Profit before zakat, tax, disc. ops 119 64 +87% 122 Net cash, operating activities 110 (212) NA (23) (1) Net cash, investing
Slide 12: The Transformation to Continue Paying Off in 2025
The Transformation to Continue Paying Off in 2025 2025 guidance Expected Developments in 2025 Indicator FY24 Actual 1H25 Actual FY25 Expectations (vs FY24) 1,682 SAR mn 886 SAR mn Revenue Increase by 7-10% (+2% YoY) (+4% YoY) Gross Profit Margin 49.8% 47.8% Stable enabled by further focus on efficie
Slide 13: Q&A Session
c 2 ni nn wu Ta) <r ore) Oo
Slide 14: Contacts
Contacts Institutional Investor Contact investor.relations@spimaco.sa Investor Relations Website https://ir.spimaco.com.sa/
Slide 15: Disclaimer
Disclaimer Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO, Tadawul: 2070) prepared this presentation on a proprietary basis as general background information about the activities of SPIMACO. The information contained herein is given in summary form and for discussion pur